|
General Information
|
|
|
Product
|
TLR9 Peptide
|
|
Description
|
Antigenic Blocking Peptide Toll-like receptor 9
|
|
Verified Applications
|
Immunocompeition, Immunodepletion
|
|
Peptide Description
|
Synthetic peptide taken within amino acid region 430-460 on human TLR9 protein. |
|
Accession #
|
GenBank: AAQ89443.1
|
|
Physical Properties
|
|
|
Quantity
|
250 µg
|
|
Volume
|
100 µl
|
|
Form
|
Antigenic Blocking Peptide
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
|
Protein
|
|
Uniprot #
|
Q9NR96
|
|
Overview
|
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides.
|
|
Molecular Function
|
Receptor, Interleukin-1 receptor binding, siRNA binding
|
|
Subcellular Location
|
Endoplasmic reticulum membrane; Single-pass type 1 membrane protein, Endosome, Lysosome, Cytoplasmic vesicle
|
|
Expression
|
Highly expressed in spleen, lymph node, tonsil and peripheral blood leukocytes, especially in plasmacytoid pre-dendritic cells. Levels are much lower in monocytes and CD11c+ immature dendritic cells. Also detected in lung and liver.
|
|
Structure
|
Interacts with MYD88 via their respective TIR domains (By similarity). Interacts (via transmembrane domain) with UNC93B1 (By similarity). Interacts with CD300LH; the interaction may promote full activation of TLR9-triggered innate responses.
|
|
Alternative Nomenclature
|
CD 289 antibody
TLR 9 antibody
Toll like receptor 9 isoform A precursor antibody
Toll like receptor 9 isoform B antibody
|
| |
|
TLR9 Antibody
TLR9 Antibody FITC
TLR9 Antibody BIOTIN
TLR9 Positive Control
